Why GlaxoSmithKline plc looks set to be beaten by Inmarsat Plc

Inmarsat plc’s (LON: ISAT) strong cash flow could help the firm beat GlaxoSmithKline plc (LON: GSK).

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

I think there’s better investment potential in the some of the smaller firms in the FTSE 100 than the 30 or so largest constituents of the index.

With that in mind, I’m attracted to satellite communications service provider Inmarsat (LSE: ISAT), which could make a better long-term investment than pharmaceuticals giant GlaxoSmithKline (LSE: GSK).

David and Goliath

Although both firms reside in the FTSE 100 index, Inmarsat’s £3,320m market capitalisation makes it a David compared to Goliath GlaxoSmithKline, which has a market cap of £69,375m.

Despite the size difference, the firms share defensive characteristics due to both operating in sectors capable of delivering steady inflows of cash.

It’s all about cash from operations

The well-reported patent-cliff headaches of recent years have made it more difficult for GlaxoSmithKline to grow as lines with high earnings lost patent exclusivity and profits plunged. However, the firm seems to remain popular in many investors’ and fund managers’ income-focused portfolios despite a record of erratic outcomes for profit and cash flow:

December

2011

2012

2013

2014

2015

Profit after tax (£m)

5,458

4,678

5,628

2,831

8,372

Net cash from operations (£m)

6,250

4,375

7,222

5,176

2,569

Meanwhile, Inmarsat describes itself as the market leader in the provision of mobile satellite services, with the largest portfolio of global satellite communications solutions and value-added services on the market.

The firm uses its fleet of 12 satellites to provide communications services to organisations operating in hard-to-get-to places where terrestrial communications are unreliable or non-existent. It’s a cash-generating business as the firm’s record shows.

December

2011

2012

2013

2014

2015

Profit before tax ($m)

250

217

103

341

282

Net cash from operations ($m)

882

656

597

645

706

Inmarsat’s profits receive strong support from cash flow.

Valuations

At today’s share price of 735p, Inmarsat trades on a forward price-to-earnings (P/E) ratio of almost 20 for 2017. GlaxoSmithKline’s forward P/E multiple runs at almost 16 for 2017. When it comes to dividends, the two firms are close with Inmarsat yielding a forward 5.3% and GlaxoSmithKline just over 5.6%. City analysts following the firms expect earnings to cover Inmarsat’s payout almost once and GlaxoSmithKline’s a little over once.  

Both firms are coming through periods of contracting earnings and expect profits to rise going forward. Inmarsat sees earnings dropping by around 23% this year and rebounding by 12% during 2017. GlaxoSmithKline expects earnings to expand by 16% this year and by 5% during 2017.

Outlooks  

In April’s first-quarter results report, GlaxoSmithKline told us that a strong performance demonstrates momentum driven by growth in sales of new products, cost control and execution of restructuring and integration plans. The firm’s new product development pipeline is also delivering encouraging results and Indeed, with earnings figures back in positive territory, it does seem as if GlaxoSmithKline is finally emerging from its dark tunnel.

Meanwhile, Inmarsat’s Q1 report in May has it that the firm’s near-term business growth will continue to be challenging but the medium-to-long-term outlook is positive.

Both firms are worth researching for their defensive characteristics but I favour Inmarsat, putting my faith in the company’s recovery potential and strong-looking cash flow.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Kevin Godbold has no position in any shares mentioned. The Motley Fool UK owns shares of and has recommended GlaxoSmithKline. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Passive income text with pin graph chart on business table
Investing Articles

Yields of up to 7%! I’d consider boosting my income with these FTSE dividend stocks

The London market has some decent-looking dividend stocks right now, and I’m tempted by these two for growing income streams.

Read more »

Young mixed-race couple sat on the beach looking out over the sea
Investing Articles

I’d put £20K in an ISA now to target a £1,900 monthly second income in future!

Christopher Ruane shares why he thinks a long-term approach to investing and careful selection of shares could help him build…

Read more »

Mature couple at the beach
Investing Articles

6 stocks that Fools have been buying!

Our Foolish freelancers are putting their money where their mouths are and buying these stocks in recent weeks.

Read more »

Black woman using loudspeaker to be heard
Investing Articles

I was right about the Barclays share price! Here’s what I think happens next

Jon Smith explains why he still feels the Barclays share price is undervalued and flags up why updates on its…

Read more »

Investing Articles

Where I’d start investing £8,000 in April 2024

Writer Ben McPoland highlights two areas of the stock market that he would target if he were to start investing…

Read more »

View of Tower Bridge in Autumn
Investing Articles

Ahead of the ISA deadline, here are 3 FTSE 100 stocks I’d consider

Jon Smith notes down some FTSE 100 stocks in sectors ranging from property to retail that he thinks could offer…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

Why I think Rolls-Royce shares will pay a dividend in 2024

Stephen Wright thinks Rolls-Royce shares are about to pay a dividend again. But he isn’t convinced this is something investors…

Read more »

Investing Articles

1 of the best UK shares to consider buying in April

Higher gold prices and a falling share price have put this FTSE 250 stock on Stephen Wright's list of UK…

Read more »